AAPS Journal

Papers
(The H4-Index of AAPS Journal is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics353
Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19280
Non-viral Vectors in Gene Therapy: Recent Development, Challenges, and Prospects174
Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit88
Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review61
FDA’s Poly (Lactic-Co-Glycolic Acid) Research Program and Regulatory Outcomes58
Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective48
Protein Corona-Enabled Systemic Delivery and Targeting of Nanoparticles41
A Cautionary Tale: Quantitative LC-HRMS Analytical Procedures for the Analysis of N-Nitrosodimethylamine in Metformin40
Understanding Drug Delivery to the Brain Using Liposome-Based Strategies: Studies that Provide Mechanistic Insights Are Essential38
Application of Machine Learning in Translational Medicine: Current Status and Future Opportunities35
Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization35
Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib34
γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology32
Discovery of a Highly Selective Sigma-2 Receptor Ligand, 1-(4-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one (CM398), with Drug-Like Properties and Antino32
Considerations and Caveats when Applying Global Sensitivity Analysis Methods to Physiologically Based Pharmacokinetic Models30
Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs27
Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays25
Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents25
Using a Physiologically Based Pharmacokinetic Absorption Model to Establish Dissolution Bioequivalence Safe Space for Oseltamivir in Adult and Pediatric Populations24
A Quantitative Systems Pharmacology Model of T Cell Engager Applied to Solid Tumor24
Use of Physiologically Based Pharmacokinetic Modeling for Predicting Drug–Food Interactions: Recommendations for Improving Predictive Performance of Low Confidence Food Effect Models24
Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors24
Amorphous Solid Dispersions Containing Residual Crystallinity: Competition Between Dissolution and Matrix Crystallization24
0.02579402923584